



NEWS RELEASE

Biosensors Announces Record Results and Executive Succession Plan

Paris, May 26, 2010 – Biosensors International Group (“Biosensors” or the “Company”; Bloomberg, BIG SP), a maker of advanced medical device technologies, announced today that it had achieved record revenues in both fourth quarter and the full financial year ending 31 March 2010. The Company also announced that Jeffrey B. Jump, currently Managing Director and Senior Vice President of Global Sales and Marketing, is to succeed Michael R. Kleine as President and Chief Executive Officer, with effect from July 1, 2010, with a seat on the Biosensors Board of Directors. Mr. Kleine will continue as a non-executive member of the board, providing support to Mr. Jump and to the Company’s Chairman, Yoh Chie Lu.

“We are delighted with our rapid growth into the DES markets of Europe, Asia, South America and India”, Mr. Kleine said. “We are particularly pleased with the regulatory, clinical, marketing and sales team that Jeff has built, which was able to enter important new markets during the last quarter, including France and Korea. We now have the right team and resources in place for that growth to continue”.

Mr. Kleine led the Company’s efforts to rationalize its global operations, restructure its debt and achieve sustainable profitability and positive operating cash flow. His leadership and mentoring helped transform Biosensors’ corporate culture and instilled a more market-driven and customer-focused outlook across the organization. “Building on an extremely successful two-and-a-half years under Mike’s leadership, Jeff will continue to drive Biosensor’s technological, clinical and commercial development around the world”, added Mr. Lu. “I am extremely pleased that Jeff has agreed to take on this exciting role and that Mike will continue as a member of our board”.

As head of the Company’s global sales and marketing operations for the past three years, Mr. Jump has transformed Biosensors’ global commercial presence, initiating direct sales activities in several European and Asian markets and orchestrating the highly successful launch of the Company’s flagship drug-eluting stent system, BioMatrix™. Under his leadership, the Company has had nine quarters of consecutive sales growth and has established itself as a leading innovator in the interventional cardiology market.

“I am honored to have been appointed to this important role, at such an exciting time in the Company’s history”, said Mr. Jump. “With the global rollout of our BioMatrix drug-eluting stent and the advanced development of our BioFreedom polymer-free stent, Biosensors is poised to become a significant force in interventional cardiology. I look forward to building upon the foundation that Yoh Chie and Mike have laid and continuing the Company’s success”.

More/..



Mr. Jump joined Biosensors in 2003 as Managing Director for Europe, Middle East and Africa. During that time he established the Company's European headquarters in Switzerland, initiated the research and development team that created the Company's unique auto-micro pipette coating process, and played a key role in designing the Company's landmark LEADERS clinical trial. In 2007, he took on the global sales and marketing role, and in 2008, the global regulatory and clinical departments were added to his responsibilities.

Prior to joining Biosensors, Mr. Jump served as CEO of Xitact Medical Simulation (acquired by Mentice AB). He also held senior managerial positions and has served on the board of various multi-national medical device companies. Mr. Jump received a Bachelor of Science degree from Indiana University, a graduate degree in management research from the University of South Australia, and a Master's degree (MSc) from the London Business School.

-Ends-

For further information, please contact:

Richard Kenyon: richard@rkpr.co.uk +44 7831 569940

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stents and open-heart surgery. It has two separate drug-eluting stent programs, BioMatrix and BioFreedom™, a completely polymer-free drug-eluting stent.